Pre-Made Simlukafusp Alfa Biosimilar, Fusion Protein targeting FAP fused with human IL2 (interleukin 2, IL-2): Recombinant therapeutic protein targeting DPPIV/FAPA/FAPalpha/SIMP for drug discovery and mechanism of action (MOA) research

Pre-Made Simlukafusp Alfa Biosimilar, Fusion Protein targeting FAP fused with human IL2 (interleukin 2, IL-2): Recombinant therapeutic protein targeting DPPIV/FAPA/FAPalpha/SIMP is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Simlukafusp alfa (SIM; FAP-IL2v) is an interleukin-2 variant moiety fused to a human antibody against fibroblast activation protein-¦Á (FAP). Simlukafusp alfa bind to FAP expressed on cancer-associated fibroblasts and mediates its accumulation in malignant lesions. Simlukafusp alfa retains binding affinity to IL-2 receptor ¦Â¦Ã without binding to IL-2R¦Á resulting in activation of immune effector NK and CD8 T cells but not regulatory T cells. FAP-IL2v is designed to increase the pool of activated immune effector cells and is intended to be a combination partner to enhance the efficacy of cancer immunotherapies.